On Jun 29, 2018 “Buy” Rating Received Krystal Biotech (KRYS) at Chardan Capital with $35 Target.

June 29, 2018 - By Ashley Edward

What Price Target Has Chardan Capital Given Krystal Biotech (KRYS)

On 28 June an analyst report was released on Krystal Biotech (KRYS) of its “Buy” Rating reiterated by analysts at Chardan Capital. The MC company coverage has begun with $35 target that indicates 136.65 % upside potential from the current price.

KRYS is reaching $14.79 during the last trading session, after increased 2.57%.Currently Krystal Biotech, Inc. is after 0.00% change in last June 29, 2017. KRYS has 5,264 shares volume. KRYS underperformed by 12.57% the S&P 500.

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States.The firm is valued at $152.48 million. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.Currently it has negative earnings. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder.

Another two news for Krystal Biotech, Inc. (NASDAQ:KRYS) were briefly brought out by: Benzinga.com on June 07, 2018 with title “40 Biggest Movers From Yesterday”. The other Streetinsider.com‘s article was titled “Chardan Capital Markets Starts Krystal Biotech (KRYS) at Buy” and brought out on June 28, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: